LOGIN  |  REGISTER

Quanterix Presenting at Canaccord Genuity 44th Annual Growth Conference

August 06, 2024 | Last Trade: US$12.88 1.10 9.34

BILLERICA, Mass. / Aug 06, 2024 / Business Wire / Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery through ultra-sensitive biomarker detection, today announced that Chief Executive Officer Masoud Toloue and Chief Financial Officer Vandana Sriram will speak in a fireside chat at the Canaccord Genuity 44th Annual Growth Conference on August 13, 2024, at 3:00 p.m., ET.

The presentation will be available virtually and participants can register using this link. The presentation will be available following the conference on Quanterix’s website here.

To learn more about Quanterix, visit www.quanterix.com/about. To learn more about Quanterix’s Simoa® technology, visit: https://www.quanterix.com/simoa-technology/.

About Quanterix

From discovery to diagnostics, Quanterix’s ultra-sensitive biomarker detection is fueling breakthroughs only made possible through its unparalleled sensitivity and flexibility. The Company’s Simoa® technology has delivered the gold standard for earlier biomarker detection in blood, serum or plasma, with the ability to quantify proteins that are far lower than the Level of Quantification (LoQ). Its industry-leading precision instruments, digital immunoassay technology and CLIA-certified Accelerator laboratory have supported research that advances disease understanding and management in neurology, oncology, immunology, cardiology and infectious disease. Quanterix has been a trusted partner of the scientific community for nearly two decades, powering research published in more than 2,900 peer-reviewed journals. Find additional information about the Billerica, Massachusetts-based company at https://www.quanterix.com or follow us on Twitter and LinkedIn.

C4 Therapeutics

Stock Quote

Featured Stock

Compass Therapeutics

Compass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...

CLICK TO LEARN MORE

Featured Stock

ClearPoint Neuro

ClearPoint Neuro is a global therapy-enabling platform company providing stereotactic navigation and delivery to the brain. Applications of our ClearPoint Neuro Navigation System include electrode lead placement, placement of catheters, and biopsy. The platform has FDA clearance and is...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page

COPYRIGHT ©2023 HEALTH STOCKS HUB